Articles tagged with: Torisel
Headline, News »
Preliminary results from an ongoing Phase 2 trial show that a combination therapy of Velcade (bortezomib) and Torisel (temsirolimus) is highly effective in reducing blood and urine levels of abnormal monoclonal protein (known as “M” protein) in multiple myeloma patients. The preliminary study results will be presented at the American Society of Hematology’s (ASH) 51st annual meeting in New Orleans on Monday, December 7.
Myeloma cells produce M proteins. Higher levels of M proteins are directly related to increased disease progression and severity.
Torisel, a drug already approved for…
Headline, News »
In a recent Phase 2 study, Torisel (temsirolimus) showed little ability to reduce blood and urine levels of abnormal monoclonal protein (known as “M” protein) in relapsed multiple myeloma patients. The results were published in the November issue of the journal Leukemia Research.
Despite recent advancement in treatment options, many myeloma patients relapse and experience disease progression. Therefore, the search continues for new alternatives to treat the disease, especially for patients where previous therapy has proved unsuccessful.
Torisel, a drug already approved for use in advanced renal cell carcinoma, shows…